Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

By J. Gillmore, M. Maurer, R. Falk, G. Merlini, T. Damy, A. Dispenzieri, A. Wechalekar, J. Berk, C. Quarta, M. Grogan and 22 more. Circulation, 2016

1,778 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/18408837db744cf107f0857602bf372333fc8705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Maurer
2. M. Grogan
3. C. Rapezzi
4. J. Gillmore
5. Y. Adler
6. A. Caforio
7. T. Damy
8. M. Fontana

Citations in the corpus

• Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (2018, neutral): “Pooled tafamidis Placebo 264 (0) 177 (0) 259 (5) 173 (4) 252 (12) 171 (6) 244 (20) 163 (14) 235 (29) 161 (16) 222 (42) 150 (27) 216 (48) 141 (36) 209 (55) 131 (46) 200 (64) 118 (59) 193 (71) 113 (64) 3 21 24 27 30”
• Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. (2021, background): “In the absence of a detectable monoclonal protein and an abnormal serum FLC ratio, the specificity of Grade 2 or 3 bone scintigraphy for cardiac ATTR when the disease is suspected has been proposed to be almost 100%.(6) Please note, however, that scintigraphy should always include single photon emis”